These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 17937462)

  • 1. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.
    Faurschou M; Sorensen IJ; Mellemkjaer L; Loft AG; Thomsen BS; Tvede N; Baslund B
    J Rheumatol; 2008 Jan; 35(1):100-5. PubMed ID: 17937462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.
    Knight A; Askling J; Granath F; Sparen P; Ekbom A
    Ann Rheum Dis; 2004 Oct; 63(10):1307-11. PubMed ID: 15130900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis.
    Faurschou M; Mellemkjaer L; Voss A; Keller KK; Hansen IT; Baslund B
    Rheumatology (Oxford); 2015 Aug; 54(8):1345-50. PubMed ID: 25234661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis.
    Faurschou M; Mellemkjaer L; Sorensen IJ; Svalgaard Thomsen B; Dreyer L; Baslund B
    Arthritis Rheum; 2009 Apr; 60(4):1187-92. PubMed ID: 19333952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer preceding Wegener's granulomatosis: a case-control study.
    Faurschou M; Mellemkjaer L; Sorensen IJ; Thomsen BS; Dreyer L; Baslund B
    Rheumatology (Oxford); 2009 Apr; 48(4):421-4. PubMed ID: 19213850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.
    Koldingsnes W; Nossent JC
    J Rheumatol; 2003 Jan; 30(1):80-8. PubMed ID: 12508394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.
    Reinhold-Keller E; Beuge N; Latza U; de Groot K; Rudert H; Nölle B; Heller M; Gross WL
    Arthritis Rheum; 2000 May; 43(5):1021-32. PubMed ID: 10817555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.
    Stone JH; Holbrook JT; Marriott MA; Tibbs AK; Sejismundo LP; Min YI; Specks U; Merkel PA; Spiera R; Davis JC; St Clair EW; McCune WJ; Ytterberg SR; Allen NB; Hoffman GS;
    Arthritis Rheum; 2006 May; 54(5):1608-18. PubMed ID: 16646004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.
    Schaapveld M; Visser O; Louwman MJ; de Vries EG; Willemse PH; Otter R; van der Graaf WT; Coebergh JW; van Leeuwen FE
    J Clin Oncol; 2008 Mar; 26(8):1239-46. PubMed ID: 18323547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
    Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
    Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate.
    Buchbinder R; Barber M; Heuzenroeder L; Wluka AE; Giles G; Hall S; Harkness A; Lewis D; Littlejohn G; Miller MH; Ryan PF; Jolley D
    Arthritis Rheum; 2008 Jun; 59(6):794-9. PubMed ID: 18512713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.
    Stone JH; Uhlfelder ML; Hellmann DB; Crook S; Bedocs NM; Hoffman GS
    Arthritis Rheum; 2001 May; 44(5):1149-54. PubMed ID: 11352248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort.
    Dreyer L; Faurschou M; Mogensen M; Jacobsen S
    Arthritis Rheum; 2011 Oct; 63(10):3032-7. PubMed ID: 21953088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
    Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
    J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignancies and cyclophosphamide exposure in Wegener's granulomatosis.
    Bernatsky S; Ramsey-Goldman R; Clarke AE
    J Rheumatol; 2008 Jan; 35(1):11-3. PubMed ID: 18176988
    [No Abstract]   [Full Text] [Related]  

  • 16. Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials.
    Heijl C; Harper L; Flossmann O; Stücker I; Scott DG; Watts RA; Höglund P; Westman K; Mahr A;
    Ann Rheum Dis; 2011 Aug; 70(8):1415-21. PubMed ID: 21616914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas.
    Chow WH; Johansen C; Gridley G; Mellemkjaer L; Olsen JH; Fraumeni JF
    Br J Cancer; 1999 Feb; 79(3-4):640-4. PubMed ID: 10027343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous cyclophosphamide in patients with chronic systemic inflammatory diseases: morbidity and mortality.
    Gøransson LG; Brodin C; Ogreid P; Janssen EA; Romundstad PR; Vatten L; Wildhagen K; Kjellevold K; Omdal R
    Scand J Rheumatol; 2008; 37(2):130-4. PubMed ID: 18415771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of malignant neoplasms after liver transplantation: a population-based study.
    Aberg F; Pukkala E; Höckerstedt K; Sankila R; Isoniemi H
    Liver Transpl; 2008 Oct; 14(10):1428-36. PubMed ID: 18825704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC; Lau CS; Wong RW
    Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.